Other Information
−Removed: Rule 10b5-1 Director and Officer Trading Arrangements
−Removed: During the three months ended October 25, 2024, certain of our officers and directors adopted “Rule 10b5-1 trading arrangements,” intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows.
−Removed: On October 10, 2024 , Brett Wall , Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan.
−Removed: Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date.
+Added: Not applicable .
+Added: Letter Agreement by and between Medtronic, Inc.
+Added: and Thierry Piéton dated December 24, 2024
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Medtronic plc
−Removed: November 26, 2024 /s/ Jennifer M.
+Added: February 25, 2025 /s/ Jennifer M.
Senior Vice President, Global Controller and Chief Accounting Officer (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.